Editorial: Bringing function to the forefront of cell therapy: how do we demonstrate potency? by Alasdair R. Fraser, Stuart M. Curbishley, Andy Roemhild, Kwong Tsang

Get full text

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid by de Graaf, K, Lapeyre, G, Guilhot, F, Ferlin, W, Curbishley, S, Carbone, M, Richardson, P, Moreea, S, McCune, C, Ryder, S, Chapman, R, Floreani, A, Jones, D, De Min, C, Adams, D, Invernizzi, P

Promises and challenges of adoptive T-cell therapies for solid tumours by Morotti, M, Albukhari, A, Alsaadi, A, Artibani, M, Brenton, JD, Curbishley, SM, Dong, T, Dustin, ML, Hu, Z, McGranahan, N, Miller, ML, Santana-Gonzalez, L, Seymour, L, Shi, T, Van Loo, P, Yau, C, White, H, Wietek, N, Church, DN, Wedge, DC, Ahmed, A